Bio View (Israel) Performance
| BIOV Stock | ILS 19.10 0.80 4.02% |
On a scale of 0 to 100, Bio View holds a performance score of 6. The firm shows a Beta (market volatility) of 1.7, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bio View will likely underperform. Please check Bio View's total risk alpha, maximum drawdown, potential upside, as well as the relationship between the treynor ratio and value at risk , to make a quick decision on whether Bio View's price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bio View are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bio View sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 17.2 M | |
| Total Cashflows From Investing Activities | -740 K |
Bio |
Bio View Relative Risk vs. Return Landscape
If you would invest 1,660 in Bio View on October 9, 2025 and sell it today you would earn a total of 250.00 from holding Bio View or generate 15.06% return on investment over 90 days. Bio View is generating 0.3982% of daily returns and assumes 4.7629% volatility on return distribution over the 90 days horizon. Simply put, 42% of stocks are less volatile than Bio, and 92% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bio View Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bio View's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bio View, and traders can use it to determine the average amount a Bio View's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0836
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIOV | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.76 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.4 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.08 actual daily | 6 94% of assets perform better |
Based on monthly moving average Bio View is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bio View by adding it to a well-diversified portfolio.
Bio View Fundamentals Growth
Bio Stock prices reflect investors' perceptions of the future prospects and financial health of Bio View, and Bio View fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bio Stock performance.
| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Profit Margin | 0.04 % | |||
| Operating Margin | 0.02 % | |||
| Current Valuation | 35.4 M | |||
| Shares Outstanding | 13.75 M | |||
| Price To Book | 1.72 X | |||
| Price To Sales | 1.71 X | |||
| Revenue | 30.51 M | |||
| EBITDA | 4.72 M | |||
| Cash And Equivalents | 17.67 M | |||
| Cash Per Share | 1.24 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 11.80 % | |||
| Book Value Per Share | 2.00 X | |||
| Cash Flow From Operations | 3.25 M | |||
| Earnings Per Share | 0.09 X | |||
| Total Asset | 40.02 M | |||
| Retained Earnings | (29 M) | |||
| Current Asset | 26 M | |||
| Current Liabilities | 8 M | |||
About Bio View Performance
By analyzing Bio View's fundamental ratios, stakeholders can gain valuable insights into Bio View's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bio View has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bio View has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel.Things to note about Bio View performance evaluation
Checking the ongoing alerts about Bio View for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bio View help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bio View had very high historical volatility over the last 90 days | |
| About 52.0% of the company shares are held by company insiders |
- Analyzing Bio View's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bio View's stock is overvalued or undervalued compared to its peers.
- Examining Bio View's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bio View's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bio View's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bio View's stock. These opinions can provide insight into Bio View's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bio Stock analysis
When running Bio View's price analysis, check to measure Bio View's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio View is operating at the current time. Most of Bio View's value examination focuses on studying past and present price action to predict the probability of Bio View's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio View's price. Additionally, you may evaluate how the addition of Bio View to your portfolios can decrease your overall portfolio volatility.
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |